Mosam Anisa, Sathar Mahomed A, Dawood Halima, Cassol Edana, Esterhuizen Tonya M, Coovadia Hoosen M
Medical Bioethics Unit, Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa.
AIDS. 2007 Jun 19;21(10):1377-9. doi: 10.1097/QAD.0b013e3281532cb8.
In 38 African AIDS patients initiating generic HAART, GB virus C (GBV-C) RNA-positive patients retained GBV-C viraemia during 52 weeks of HAART, had a faster decline in HIV viral load (P = 0.03), fewer opportunistic infections (14.3 versus 50%, P = 0.18), and suffered no serious adverse events (none versus 61%, P = 0.008) compared with patients without GBV-C. GBV-C co-infection may be associated with a beneficial effect on African AIDS patients treated with generic HAART.
在38名开始接受非专利高效抗逆转录病毒治疗(HAART)的非洲艾滋病患者中,与无GB病毒C(GBV-C)感染的患者相比,GBV-C RNA阳性患者在HAART治疗的52周期间维持GBV-C病毒血症,HIV病毒载量下降更快(P = 0.03),机会性感染更少(14.3%对50%,P = 0.18),且未发生严重不良事件(0对61%,P = 0.008)。GBV-C合并感染可能对接受非专利HAART治疗的非洲艾滋病患者具有有益作用。